While the glucose lowering action of thiazolidinediones (TZDs) waswell-known as early as 1988 [1], it was not until 1995 that the nuclearreceptor PPARγ was identified as their target [2] andthat its activation was shown to be responsible for their therapeutic benefits.PPARγ full agonists, including the TZDs rosiglitazone(Avandia) and pioglitazone (Actos) are powerful drugs for the treatment ofinsulin resistance associated with type-2 diabetes mellitus (T2DM) [3]. Here, PPARG is linked to diabetes mellitus.